Litcius/Paper detail

LBA75 Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial

Lars Bergmann, Marit Ahrens, L. Albiges, M. Gross Goupil, Ekaterini Boleti, Gwénaëlle Gravis, A. Flechon, M-O.J. Grimm, S. Rausch, P. Barthelemy, D.E. Castellano Gauna, B. Mellado González, P. Ivanyi, A. Floercken, C. Suarez Rodriguez, J.P. Maroto Rey, V. Gruenwald, Iris Burkholder, A. Hartmann, John B.A.G. Haanen

2024Annals of Oncology20 citationsDOIOpen Access PDF

Topics & Concepts

MedicineNivolumabIpilimumabInternal medicineOncologyRenal cell carcinomaStandard of careCancerImmunotherapyRenal cell carcinoma treatmentEconomic and Financial Impacts of CancerCancer Immunotherapy and Biomarkers
LBA75 Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial | Litcius